TrialsgrambetaRCTs are beautiful

CRASH-3

2019

Tranexamic Acid in Traumatic Brain Injury

In 12,737 patients with traumatic brain injury, tranexamic acid did not reduce head-injury death overall versus placebo, with benefit in mild–moderate TBI.

Result

Efficacy: Head-injury-related death within 28 daysRR 0.94 (95% CI 0.86-1.02)

Below 1 favours tranexamic acid, above 1 favours placebo.

Event rates
Absolute difference
1.3 points

The absolute difference is derived from the event rates.

Also reported: Mild–moderate TBI subgroup benefit.

Original publication
Subtopic
Tranexamic acid
Design
International RCT
Relevance
Supporting: context rather than must-know.
Source
CRASH-3 Trial Collaborators. Lancet. 2019;394(10210):1713-1723.doi 10.1016/S0140-6736(19)32233-0

Discussion & critique

Modest overall, but supports early TXA for mild–moderate TBI given the low cost and safety.

Discussed in podcasts